The management of axillary lymph nodes in breast cancer is continually evolving. Recent data now support omitting axillary lymph node dissection (ALND) in most patients with metastases in up to two ...

The 3-year axillary RFS rate was 99.2% with axillary lymph node dissection and 98.8% with less-invasive procedures. Less-invasive lymph node procedures are noninferior to axillary lymph node ...

Background: Currently, the axillary management strategy of omitting axillary lymph node dissection (ALND) in early-stage breast cancer (BC) patients with cT1-2, clinically node-negative (cN0), and ...

Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea Purpose: With the advancement of neoadjuvant chemotherapy (NAC ...

Abstract: Prediction of axillary lymph node metastasis in breast cancer is a critical factor in determining the prognosis of breast cancer patients and the necessity of axillary intervention. However, ...

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment. Targeted axillary dissection is used for ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Sentinel lymph node biopsy has replaced traditional axillary dissection, minimizing lymphedema risk in breast cancer surgery. The procedure targets the first draining lymph nodes, reducing unnecessary ...

oDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden pDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden ...